The idea that a government-run drug insurance monopoly will cost less and deliver the same benefits as the current system is laughable. The Parliamentary Budget Office estimated that even a bare-bones pharmacare plan would impose a net additional tax burden of at least $7.3 billion. CHPI estimated that pharmacare will shift over $25 billion off the provinces and the private sector onto the federal budget, including more than $13 billion in new costs for taxpayers, assuming no changes to prices and drug plan benefits. The policy illogic for pharmacare is baffling. Governments say that public plans can’t currently afford to cover new drugs, but they are contemplating shifting billions of dollars in privately insured drug costs onto government budgets.